baricitinib vs Ruxolitinib (Opzelura)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK1/2 · full Atopic Dermatitis pipeline
baricitinib · Olumiant
Marketed by Eli Lilly and partners
NCT03334396 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial of 660 participants. The primary clinical endpoint was met for both 2 mg and 4 mg baricitinib: 11.4% and 16.8% achieved the specified IGA response versus 4.8% with placebo, with statistically significant comparisons.
Next expected readout: May 2030 · NCT07262983 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5% (met)
Result source: NCT03334422
Ruxolitinib (Opzelura)
Marketed by Incyte and partners
NCT03745638 · Phase 3 · completed
This was a randomized, quadruple-blinded, vehicle-controlled Phase 3 trial with 631 participants, comparing two doses of ruxolitinib cream against placebo. The primary endpoint was a clinician-assessed measure of disease severity (IGA treatment success at Week 8), and the comparison was met decisively: both ruxolitinib groups achieved significantly higher response rates than vehicle (50.0% and 53.8% vs 15.1%, each p<0.0001). The sample size was adequate, treatment assignment was concealed, and the hard clinical endpoint clearly favored active treatment.
Next expected readout: August 2027 · NCT07661979 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5) (met)
Result source: NCT03745638
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | baricitinib | Ruxolitinib (Opzelura) |
|---|---|---|
| EASI-75 | 31.5% vs 17.2%+14.3 vs placeboNCT0342810065 other results
| 70% vs 18.5%+51.5 vs placeboNCT0623881721 other results
|
| IGA 0/1 with 2-point improvement | 13% vs 12.9%+0.1 vs placeboNCT034281005 other results
| 15.7% vs 9.6%+6.1 vs placeboNCT0301189211 other results
|
| EASI-90 | 16% vs 4.8%+11.2 vs placeboNCT0333439615 other results
| 38.1% vs 9.5%+28.6 vs placeboNCT0374563811 other results
|
| EASI, % change | -59.4% vs -34.8%−24.5 vs placeboNCT0333439612 other results
| -71.0% vs -37.9%−33.1 vs placeboNCT0374563831 other results
|
EASI-75
- baricitinib
- 31.5% vs 17.2%+14.3 vs placeboNCT03428100
65 other results
- 27.6% vs 17.2% NCT03428100
- 29.5% vs 8.2% NCT03435081
- 39.8% vs 54.3% NCT03334435
- 73.8% vs 43.5% NCT03334435
- 37% vs 26.9% NCT03428100
- 25% vs 17.2% NCT03428100
- 47.7% vs 22.9% NCT03733301
- 40.9% vs 54.3% NCT03334435
- 30.3% vs 26.9% NCT03428100
- 27.6% vs 17.2% NCT03428100
- 12.9% vs 8.2% NCT03435081
- 76.7% vs 55.1% NCT03334435
- 79.8% vs 44.6% NCT03334435
- 93% vs 63.3% NCT03334435
- 51.4% vs 38.5% NCT03334435
- 42.9% vs 38.2% NCT03334435
- 51.4% vs 44.2% NCT03334435
- 44.4% vs 47.1% NCT03334435
- 24.8% vs 8.8% NCT03334396
- 21.1% vs 6.1% NCT03334422
- 61.5% vs 71.4% NCT03334435
- 64.3% vs 42.3% NCT03334435
- 55.6% vs 55.9% NCT03334435
- 58.3% vs 43.5% NCT03334435
- 72.8% vs 43.5% NCT03334435
- 74.4% vs 55.1% NCT03334435
- 83.3% vs 55.1% NCT03334435
- 58.3% vs 44.6% NCT03334435
- 73.9% vs 44.6% NCT03334435
- 68.2% vs 72.4% NCT03428100
- 76.7% vs 63.3% NCT03334435
- 83.3% vs 63.3% NCT03334435
- 53.2% vs 71.4% NCT03334435
- 55.1% vs 71.4% NCT03334435
- 64.8% vs 38.5% NCT03334435
- 52.8% vs 38.2% NCT03334435
- 74.1% vs 44.2% NCT03334435
- 47.2% vs 47.1% NCT03334435
- 18.7% vs 8.8% NCT03334396
- 17.9% vs 6.1% NCT03334422
- 70.4% vs 42.3% NCT03334435
- 67.9% vs 55.9% NCT03334435
- 43.1% vs 22.9% NCT03733301
- 58.2% vs 43.5% NCT03334435
- 63.6% vs 62.1% NCT03428100
- 79.2% vs 55.1% NCT03334435
- 65.6% vs 54.3% NCT03334435
- 70.6% vs 72.4% NCT03428100
- 69.2% vs 44.6% NCT03334435
- 89.6% vs 63.3% NCT03334435
- 44.4% vs 71.4% NCT03334435
- 76.5% vs 62.1% NCT03428100
- 51.1% vs 38.5% NCT03334435
- 33.3% vs 26.9% NCT03428100
- 46.7% vs 44.2% NCT03334435
- 30.1% vs 17.2% NCT03428100
- 17.3% vs 8.8% NCT03334396
- 12.8% vs 6.1% NCT03334422
- 62.2% vs 42.3% NCT03334435
- 22.6% vs 17.2% NCT03428100
- 32.2% vs 32% NCT03952559
- 40% vs 32% NCT03952559
- 52.5% vs 32% NCT03952559
- 85.7% vs 72.4% NCT03428100
- 57.1% vs 62.1% NCT03428100
- Ruxolitinib (Opzelura)
- 70% vs 18.5%+51.5 vs placeboNCT06238817
21 other results
- 56% vs 24.6% NCT03745638
- 62.1% vs 24.6% NCT03745638
- 51.5% vs 14.4% NCT03745651
- 61.8% vs 14.4% NCT03745651
- 51.5% vs 15.4% NCT04921969
- 67.2% vs 15.4% NCT04921969
- 51.6% vs 14.3% NCT03745638
- 58.5% vs 14.3% NCT03745638
- 42% vs 10.2% NCT03745651
- 50.4% vs 10.2% NCT03745651
- 53% vs 12.3% NCT04921969
- 62.6% vs 12.3% NCT04921969
- 30.2% vs 5.6% NCT03745638
- 36% vs 5.6% NCT03745638
- 25.5% vs 4.2% NCT03745651
- 31.6% vs 4.2% NCT03745651
- 35.8% vs 6.2% NCT04921969
- 43.5% vs 6.2% NCT04921969
- 33.3% vs 35.3% NCT05127421
- 29.2% vs 33.3% NCT05127421
- 10.4% vs 5.6% NCT05127421
IGA 0/1 with 2-point improvement
- baricitinib
- 13% vs 12.9%+0.1 vs placeboNCT03428100
5 other results
- 21.7% vs 9.7% NCT03428100
- 18.9% vs 12.9% NCT03428100
- 15.1% vs 9.7% NCT03428100
- 20.4% vs 12.9% NCT03428100
- 12.9% vs 9.7% NCT03428100
- Ruxolitinib (Opzelura)
- 15.7% vs 9.6%+6.1 vs placeboNCT03011892
11 other results
- 31.4% vs 9.6% NCT03011892
- 30.8% vs 9.6% NCT03011892
- 48% vs 9.6% NCT03011892
- 9.8% vs 7.7% NCT03011892
- 13.7% vs 7.7% NCT03011892
- 21.2% vs 7.7% NCT03011892
- 38% vs 7.7% NCT03011892
- 5.9% vs 1.9% NCT03011892
- 4.1% vs 1.9% NCT03011892
- 13.5% vs 1.9% NCT03011892
- 8% vs 1.9% NCT03011892
EASI-90
- baricitinib
- 16% vs 4.8%+11.2 vs placeboNCT03334396
15 other results
- 13% vs 2.5% NCT03334422
- 14.1% vs 6.5% NCT03428100
- 24.3% vs 13.8% NCT03733301
- 10.6% vs 4.8% NCT03334396
- 8.9% vs 2.5% NCT03334422
- 10.3% vs 6.5% NCT03428100
- 20.5% vs 3.4% NCT03435081
- 16.5% vs 13.8% NCT03733301
- 8.7% vs 4.8% NCT03334396
- 6.4% vs 2.5% NCT03334422
- 8.6% vs 6.5% NCT03428100
- 7.5% vs 3.4% NCT03435081
- 11.6% vs 12.3% NCT03952559
- 21.7% vs 12.3% NCT03952559
- 30% vs 12.3% NCT03952559
- Ruxolitinib (Opzelura)
- 38.1% vs 9.5%+28.6 vs placeboNCT03745638
11 other results
- 44.3% vs 9.5% NCT03745638
- 35.1% vs 4.2% NCT03745651
- 43.4% vs 4.2% NCT03745651
- 30.6% vs 4% NCT03745638
- 36.4% vs 4% NCT03745638
- 25.5% vs 2.5% NCT03745651
- 32.5% vs 2.5% NCT03745651
- 12.7% vs 2.4% NCT03745638
- 19.8% vs 2.4% NCT03745638
- 10.8% vs 0.8% NCT03745651
- 15.8% vs 0.8% NCT03745651
EASI, % change
- baricitinib
- -59.4% vs -34.8%−24.5 vs placeboNCT03334396
12 other results
- -54.9% vs -28.9% NCT03334422
- -63.3% vs -42.7% NCT03428100
- -67.2% vs -45.1% NCT03733301
- -51.9% vs -34.8% NCT03334396
- -56.0% vs -42.7% NCT03428100
- -54.8% vs -28.9% NCT03334422
- -54.4% vs -34.1% NCT03435081
- -58.2% vs -45.1% NCT03733301
- -48.2% vs -34.8% NCT03334396
- -41.7% vs -28.9% NCT03334422
- -60.3% vs -42.7% NCT03428100
- -46.7% vs -34.1% NCT03435081
- Ruxolitinib (Opzelura)
- -71.0% vs -37.9%−33.1 vs placeboNCT03745638
31 other results
- -77.4% vs -37.9% NCT03745638
- -73.4% vs -28.8% NCT03745651
- -74.8% vs -28.8% NCT03745651
- -68.0% vs -23.0% NCT03745638
- -71.1% vs -23.0% NCT03745638
- -65% vs -20.4% NCT03745651
- -66.3% vs -20.4% NCT03745651
- -51.8% vs -16.3% NCT03745638
- -56.6% vs -16.3% NCT03745638
- -45.9% vs -13.9% NCT03745651
- -49.1% vs -13.9% NCT03745651
- -71.6% vs -11.9% NCT03011892
- -50.2% vs -21.9% NCT03011892
- -58.4% vs -21.9% NCT03011892
- -67.0% vs -21.9% NCT03011892
- -79.0% vs -21.9% NCT03011892
- -44.9% vs -11.9% NCT03011892
- -52.8% vs -11.9% NCT03011892
- -66.7% vs -11.9% NCT03011892
- -45.4% vs -15.5% NCT03011892
- -52.2% vs -15.5% NCT03011892
- -67% vs -15.5% NCT03011892
- -71.6% vs -15.5% NCT03011892
- -30.0% vs -4.8% NCT03011892
- -45.9% vs -4.8% NCT03011892
- -49.9% vs -4.8% NCT03011892
- -52.7% vs -4.8% NCT03011892
- -44.9% vs -59.5% NCT03011892
- -52.8% vs -59.5% NCT03011892
- -66.7% vs -59.5% NCT03011892
- -71.6% vs -59.5% NCT03011892
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety
Coverage. baricitinib: 15 of 15 rows · Ruxolitinib (Opzelura): 15 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | baricitinib Rows use multiple source trials | Ruxolitinib (Opzelura) Rows use multiple source trials |
|---|---|---|
| BSA absolute change · percentage points | -25.66% (n=115) vs -20.31% (n=105) placebo @ 16wkHigh Dosea,b,c,d NCT03952559 · Phase 3 · registry result, not featured evidence show 2 more doses-21.83% (n=109) vs -20.31% (n=105) placebo @ 16wkLow Dose NCT03952559 · Phase 3 · registry result, not featured evidence -22.06% (n=113) vs -20.31% (n=105) placebo @ 16wkMedium Dose NCT03952559 · Phase 3 · registry result, not featured evidence | -6.3% (n=252) vs -2.51% (n=126) placebo @ 8wk0.75% Cream BIDa,b,c,d NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose-6.54% (n=253) vs -2.51% (n=126) placebo @ 8wk1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 |
| CDLQI absolute change · score | -3.36 vs -3.06 placebo score @ 16wkHigh Dosea,b,c,d NCT03952559 · Phase 3 · registry result, not featured evidence show 2 more doses-3.73 vs -3.06 placebo score @ 16wkLow Dose NCT03952559 · Phase 3 · registry result, not featured evidence -3.7 vs -3.06 placebo score @ 16wkMedium Dose NCT03952559 · Phase 3 · registry result, not featured evidence | -5.88 vs -2.31 placebo score @ 8wk0.75% Cream BIDa,b,c,d NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose-7.61 vs -2.31 placebo score @ 8wk1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 |
| DLQI absolute change · score | -6.76 vs -2.46 placebo score @ 16wk4 mga,e,d NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 2 more doses-4.3 vs -2.46 placebo score @ 16wk2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 -4.64 vs -2.46 placebo score @ 16wk1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | -7.28 vs -2.83 placebo score @ 8wk0.75% Cream BIDa,e,d NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose-7.72 vs -2.83 placebo score @ 8wk1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 |
| EASI-50 responder rate · % of participants | 41.6% (n=125) vs 15.3% (n=249) placebo @ 16wk4 mga,e,d NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 2 more doses30.1% (n=123) vs 15.3% (n=249) placebo @ 16wk2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 26% (n=127) vs 15.3% (n=249) placebo @ 16wk1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | 69.4% (n=252) vs 43.7% (n=126) placebo @ 8wk0.75% Cream BIDa,e,d NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose77.9% (n=253) vs 43.7% (n=126) placebo @ 8wk1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 |
| IGA 0/1 responder rate · % of participants | 15.4% (n=123) vs 3.7% (n=244) placebo @ 4wk4 mga,e NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 2 more doses8.1% (n=123) vs 3.7% (n=244) placebo @ 4wk2 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3.2% (n=125) vs 3.7% (n=244) placebo @ 4wk1 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | 53.2% (n=252) vs 15.1% (n=126) placebo @ 4wk0.75% Cream BIDa,e NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose54.9% (n=253) vs 15.1% (n=126) placebo @ 4wk1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 |
| IGA 0/1 responder rate · % of participants No placebo or comparator arm | 12.3% (n=81) @ 52wk4 mga,b,c NCT03334435 · Phase 3 · registry result, not featured evidence show 11 more doses15.4% (n=78) @ 52wk4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 19% (n=21) @ 52wk4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 20.5% (n=156) @ 52wk4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 5.1% (n=39) @ 52wk4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 23.7% (n=194) @ 52wk4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 10.7% (n=28) @ 52wk4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 12.6% (n=87) @ 52wk2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 19% (n=84) @ 52wk2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 15% (n=20) @ 52wk2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 20.6% (n=180) @ 52wk2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 5.9% (n=34) @ 52wk2 mg NCT03334435 · Phase 3 · registry result, not featured evidence | 76.9% (n=222) @ 52wk0.75% Creama,b,c NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose75.4% (n=225) @ 52wk1.5% Cream NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 |
| Itch NRS absolute change · score | -33.16 vs -15.35 placebo score @ 24wk4 mga,b,c,f NCT03428100 · Phase 3 · registry result, not featured evidence show 2 more doses-30.11 vs -15.35 placebo score @ 24wk2 mg NCT03428100 · Phase 3 · registry result, not featured evidence -29.35 vs -15.35 placebo score @ 24wk1 mg NCT03428100 · Phase 3 · registry result, not featured evidence | -3.14 vs -1.54 placebo score @ 8wk0.75% Cream BIDa,b,c,f NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose-3.53 vs -1.54 placebo score @ 8wk1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 |
| Itch NRS ≥4 responder rate · % of participants | 35.5% (n=62) vs 16.4% (n=55) placebo @ 16wkHigh Dosea,b,c,d NCT03952559 · Phase 3 · registry result, not featured evidence show 2 more doses17.5% (n=63) vs 16.4% (n=55) placebo @ 16wkLow Dose NCT03952559 · Phase 3 · registry result, not featured evidence 25.8% (n=62) vs 16.4% (n=55) placebo @ 16wkMedium Dose NCT03952559 · Phase 3 · registry result, not featured evidence | 42.7% (n=157) vs 16.3% (n=80) placebo @ 8wk0.75% cream BIDa,b,c,d NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose50.7% (n=146) vs 16.3% (n=80) placebo @ 8wk1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 |
| Itch NRS 4-Point Improvement responder rate · % of participants | 21.5% (n=107) vs 7.2% (n=222) placebo @ 16wk4 mga,e,d NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 2 more doses12% (n=100) vs 7.2% (n=222) placebo @ 16wk2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 10.5% (n=105) vs 7.2% (n=222) placebo @ 16wk1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | 40.4% (n=156) vs 15.4% (n=78) placebo @ 8wk0.75% Cream BIDa,e,d NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose52.2% (n=161) vs 15.4% (n=78) placebo @ 8wk1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 |
| POEM absolute change · score | -7.56 vs -1.48 placebo score @ 16wk4 mga,e,d NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 2 more doses-7.06 vs -1.48 placebo score @ 16wk2 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 -3.85 vs -1.48 placebo score @ 16wk1 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | -10.6 vs -4.3 placebo score @ 8wk0.75% Cream BIDa,e,d NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose-11.82 vs -4.3 placebo score @ 8wk1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 |
| Skin Pain NRS absolute change · score | -1.93 vs -0.84 placebo score @ 16wk4 mga,e,d NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 2 more doses-1.58 vs -0.84 placebo score @ 16wk2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 -1.92 vs -0.84 placebo score @ 16wk1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | -2.55 vs -1.16 placebo score @ 8wk0.75% Cream BIDa,e,d NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 1 more dose-2.84 vs -1.16 placebo score @ 8wk1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 |
| Dropout rate | 4%4 mgg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 50 more results—4 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8.1%2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8.7%1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 4.9%4 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8.1%2 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8%1 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —High Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Low Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Medium Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Mid Dose NCT03952559 · Phase 3 · registry result, not featured evidence —High Dose NCT03952559 · Phase 3 · registry result, not featured evidence —4 mg NCT03334435 · Phase 3 · registry result, not featured evidence —4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 98%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 97.7%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 7.6%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —Placebo to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 6.5%2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —Placebo to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 14%1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 13%2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —1 mg NCT03435081 · Phase 3 · registry result, not featured evidence —1 mg NCT03435081 · Phase 3 · registry result, not featured evidence 3.6%4 mg NCT03733301 · Phase 3 · registry result, not featured evidence 8.3%2 mg NCT03733301 · Phase 3 · registry result, not featured evidence —4 mg NCT02576938 · Phase 2 · registry result, not featured evidence 32.4%2 mg NCT02576938 · Phase 2 · registry result, not featured evidence | —0.75% Creamh NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 32 more results—1.5% Cream NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 11.9%0.75% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 11.1%1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 15.7%0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8.9%1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 10.7%1.5% Cream BID NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% Cream BID NCT04921969 · Phase 3 —1.5% Cream BID NCT04921969 · Phase 3 —0.75% Cream BID NCT04921969 · Phase 3 —1.5% Cream BID NCT04921969 · Phase 3 10.4%0.75% Cream BID NCT04921969 · Phase 3 12.2%1.5% Cream BID NCT04921969 · Phase 3 3.1%1.5% NCT06238817 · Phase 3 · registry result, not featured evidence 11.1%1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence 10.2%1.5% Cream BID NCT04839380 · Phase 2 · registry result, not featured evidence 13.7%0.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence 10%1.5% BID NCT03011892 · Phase 2 · registry result, not featured evidence 13.5%1.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence —0.15% QD NCT03011892 · Phase 2 · registry result, not featured evidence —0.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence —1.5% BID NCT03011892 · Phase 2 · registry result, not featured evidence —1.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%4 mgg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 50 more results—4 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.6%4 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.6%2 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2.4%1 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —High Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Low Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Medium Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Mid Dose NCT03952559 · Phase 3 · registry result, not featured evidence —High Dose NCT03952559 · Phase 3 · registry result, not featured evidence —4 mg NCT03334435 · Phase 3 · registry result, not featured evidence —4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 3.1%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 1.7%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 1.1%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —Placebo to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 1.6%2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —Placebo to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 0%1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 1.4%2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —1 mg NCT03435081 · Phase 3 · registry result, not featured evidence —1 mg NCT03435081 · Phase 3 · registry result, not featured evidence 2.7%4 mg NCT03733301 · Phase 3 · registry result, not featured evidence 0.9%2 mg NCT03733301 · Phase 3 · registry result, not featured evidence —4 mg NCT02576938 · Phase 2 · registry result, not featured evidence 8.1%2 mg NCT02576938 · Phase 2 · registry result, not featured evidence | —0.75% Creamh NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 32 more results—1.5% Cream NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%0.75% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.4%1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.4%0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% Cream BID NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% Cream BID NCT04921969 · Phase 3 —1.5% Cream BID NCT04921969 · Phase 3 —0.75% Cream BID NCT04921969 · Phase 3 —1.5% Cream BID NCT04921969 · Phase 3 0.7%0.75% Cream BID NCT04921969 · Phase 3 0.8%1.5% Cream BID NCT04921969 · Phase 3 0%1.5% NCT06238817 · Phase 3 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence —1.5% Cream BID NCT04839380 · Phase 2 · registry result, not featured evidence 0%0.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence 0%1.5% BID NCT03011892 · Phase 2 · registry result, not featured evidence 0%1.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence —0.15% QD NCT03011892 · Phase 2 · registry result, not featured evidence —0.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence —1.5% BID NCT03011892 · Phase 2 · registry result, not featured evidence —1.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 1.6%4 mgg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 50 more results0%4 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%4 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2.4%2 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 7.3%1 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%High Dose NCT03952559 · Phase 3 · registry result, not featured evidence 1.7%Low Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Medium Dose NCT03952559 · Phase 3 · registry result, not featured evidence 0.8%Mid Dose NCT03952559 · Phase 3 · registry result, not featured evidence 0%High Dose NCT03952559 · Phase 3 · registry result, not featured evidence 9.5%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 13.1%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 5.4%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 6.4%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 3.3%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 1.2%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 4.2%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 9.4%1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 1.1%1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 2.2%1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 10.9%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 16.7%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 28.6%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 16.7%Placebo to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 18.8%4 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 18.8%4 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 4.9%2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 4.5%2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 11.1%2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 19.2%2 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 9.1%Placebo to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 16%2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 12.5%2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 7.5%1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 2.9%1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 15.4%1 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 21.4%1 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence 1.4%2 mg NCT03435081 · Phase 3 · registry result, not featured evidence 0%2 mg NCT03435081 · Phase 3 · registry result, not featured evidence 0.7%1 mg NCT03435081 · Phase 3 · registry result, not featured evidence 0%1 mg NCT03435081 · Phase 3 · registry result, not featured evidence 3.6%4 mg NCT03733301 · Phase 3 · registry result, not featured evidence 1.8%2 mg NCT03733301 · Phase 3 · registry result, not featured evidence 2.6%4 mg NCT02576938 · Phase 2 · registry result, not featured evidence 5.4%2 mg NCT02576938 · Phase 2 · registry result, not featured evidence | —0.75% Creamh NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 32 more results—1.5% Cream NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3%0.75% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2%1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2.7%0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.3%1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.9%1.5% Cream BID NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% Cream BID NCT04921969 · Phase 3 —1.5% Cream BID NCT04921969 · Phase 3 0%0.75% Cream BID NCT04921969 · Phase 3 1.9%1.5% Cream BID NCT04921969 · Phase 3 —0.75% Cream BID NCT04921969 · Phase 3 —1.5% Cream BID NCT04921969 · Phase 3 2%1.5% NCT06238817 · Phase 3 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence 0%1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence 0%1.5% Cream BID NCT04839380 · Phase 2 · registry result, not featured evidence —0.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence —1.5% BID NCT03011892 · Phase 2 · registry result, not featured evidence —1.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence 0%0.15% QD NCT03011892 · Phase 2 · registry result, not featured evidence 0%0.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence 0%1.5% BID NCT03011892 · Phase 2 · registry result, not featured evidence 0%1.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 4 mgg nasopharyngitis 9.6% (placebo 10.4%) headache 8% (placebo 6.4%) cough 3.2% (placebo 0.8%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 47 more results4 mg abdominal pain 12.5% (placebo 0.4%) nausea 12.5% (placebo 0.8%) oedema peripheral 12.5% (placebo 0.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 mg headache 11.4% (placebo 6.4%) nasopharyngitis 9.8% (placebo 10.4%) abdominal pain 2.4% (placebo 0.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 mg pyrexia 12.5% (placebo 0%) urinary tract infection 12.5% (placebo 1.6%) abdominal pain 0% (placebo 0.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1 mg nasopharyngitis 17.3% (placebo 10.4%) diarrhoea 7.1% (placebo 2.8%) headache 5.5% (placebo 6.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1 mg pyrexia 20% (placebo 0%) abdominal pain 0% (placebo 0.4%) anaemia 0% (placebo 0.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 4 mg headache 8.9% (placebo 2%) nasopharyngitis 8.1% (placebo 12.3%) blood creatine phosphokinase increased 5.7% (placebo 0.4%) NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 mg nasopharyngitis 13% (placebo 12.3%) headache 7.3% (placebo 2%) herpes simplex 5.7% (placebo 0.8%) NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1 mg nasopharyngitis 10.5% (placebo 12.3%) headache 4.8% (placebo 2%) blood creatine phosphokinase increased 3.2% (placebo 0.4%) NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 High Dose abdominal pain 5% (placebo 2.5%) acne 5% (placebo 4.1%) headache 5% (placebo 8.2%) NCT03952559 · Phase 3 · registry result, not featured evidence Low Dose headache 5.8% (placebo 8.2%) bronchitis 5% (placebo 0.8%) covid-19 4.2% (placebo 2.5%) NCT03952559 · Phase 3 · registry result, not featured evidence Mid Dose headache 9.2% (placebo 8.2%) abdominal pain 4.2% (placebo 2.5%) covid-19 4.2% (placebo 2.5%) NCT03952559 · Phase 3 · registry result, not featured evidence High Dose nasopharyngitis 6.1% (placebo 4.9%) abdominal pain upper 3% (placebo 0.8%) chapped lips 3% (placebo 0%) NCT03952559 · Phase 3 · registry result, not featured evidence 4 mg covid-19 11% (placebo 2.2%) herpes zoster 9.8% (placebo 0%) nasopharyngitis 9.8% (placebo 5.4%) NCT03334435 · Phase 3 · registry result, not featured evidence 4 mg covid-19 16.7% (placebo 2.2%) nasopharyngitis 13.1% (placebo 5.4%) blood creatine phosphokinase increased 6% (placebo 1.1%) NCT03334435 · Phase 3 · registry result, not featured evidence 4 mg nasopharyngitis 16.4% (placebo 5.4%) upper respiratory tract infection 5.9% (placebo 4.3%) oral herpes 5.4% (placebo 1.1%) NCT03334435 · Phase 3 · registry result, not featured evidence 2 mg covid-19 13.3% (placebo 2.2%) nasopharyngitis 10.8% (placebo 5.4%) headache 5.6% (placebo 3.3%) NCT03334435 · Phase 3 · registry result, not featured evidence 2 mg covid-19 15.2% (placebo 2.2%) nasopharyngitis 10.9% (placebo 5.4%) headache 5.4% (placebo 3.3%) NCT03334435 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 9.5% (placebo 5.4%) urinary tract infection 7.1% (placebo 1.1%) covid-19 4.8% (placebo 2.2%) NCT03334435 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 13.8% (placebo 5.4%) headache 6% (placebo 3.3%) upper respiratory tract infection 5.6% (placebo 4.3%) NCT03334435 · Phase 3 · registry result, not featured evidence 1 mg covid-19 21.9% (placebo 2.2%) alanine aminotransferase increased 9.4% (placebo 0%) dermal cyst 6.3% (placebo 0%) NCT03334435 · Phase 3 · registry result, not featured evidence 1 mg covid-19 9.9% (placebo 2.2%) vulvovaginal candidiasis 6.7% (placebo 0%) folliculitis 5.5% (placebo 0%) NCT03334435 · Phase 3 · registry result, not featured evidence 1 mg nasopharyngitis 20% (placebo 5.4%) pyrexia 4.4% (placebo 0%) blood creatine phosphokinase increased 2.2% (placebo 1.1%) NCT03334435 · Phase 3 · registry result, not featured evidence 4 mg nasopharyngitis 37% (placebo 10.3%) influenza 15.2% (placebo 3.4%) headache 10.9% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 4 mg covid-19 16.7% (placebo 13.8%) dysmenorrhoea 14.3% (placebo 0%) upper respiratory tract infection 12.5% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 4 mg nasopharyngitis 57.1% (placebo 10.3%) covid-19 28.6% (placebo 13.8%) gastroenteritis 28.6% (placebo 0%) NCT03428100 · Phase 3 · registry result, not featured evidence Placebo to 4 mg nasopharyngitis 50% (placebo 10.3%) abdominal pain upper 16.7% (placebo 0%) migraine 16.7% (placebo 0%) NCT03428100 · Phase 3 · registry result, not featured evidence 4 mg to 2 mg nasopharyngitis 18.8% (placebo 10.3%) upper respiratory tract infection 18.8% (placebo 3.4%) arthralgia 12.5% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 4 mg to 4 mg covid-19 25% (placebo 13.8%) bronchitis 18.8% (placebo 0%) herpes simplex 18.8% (placebo 6.9%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 19.6% (placebo 10.3%) influenza 8.2% (placebo 3.4%) headache 7.6% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 22.7% (placebo 10.3%) covid-19 18.2% (placebo 13.8%) herpes zoster 13.6% (placebo 0%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg to 2 mg covid-19 14.8% (placebo 13.8%) vulvovaginal candidiasis 14.3% (placebo 0%) nasopharyngitis 11.1% (placebo 10.3%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg to 4 mg covid-19 19.2% (placebo 13.8%) herpes zoster 15.4% (placebo 0%) skin infection 15.4% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence Placebo to 2 mg acne 9.1% (placebo 0%) anaemia 9.1% (placebo 0%) covid-19 9.1% (placebo 13.8%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg to 2 mg headache 20% (placebo 3.4%) vulvovaginal candidiasis 20% (placebo 0%) covid-19 16% (placebo 13.8%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg to 1 mg nasopharyngitis 33.3% (placebo 10.3%) covid-19 12.5% (placebo 13.8%) pain in extremity 12.5% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 1 mg nasopharyngitis 17.2% (placebo 10.3%) folliculitis 9.7% (placebo 0%) headache 8.6% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 1 mg dysmenorrhoea 23.1% (placebo 0%) covid-19 17.6% (placebo 13.8%) nasopharyngitis 11.8% (placebo 10.3%) NCT03428100 · Phase 3 · registry result, not featured evidence 1 mg to 2 mg herpes simplex 15.4% (placebo 6.9%) herpes zoster 15.4% (placebo 0%) nasopharyngitis 15.4% (placebo 10.3%) NCT03428100 · Phase 3 · registry result, not featured evidence 1 mg to 4 mg conjunctivitis 21.4% (placebo 0%) covid-19 21.4% (placebo 13.8%) uterine polypectomy 16.7% (placebo 0%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg upper respiratory tract infection 6.9% (placebo 6.2%) nasopharyngitis 6.2% (placebo 7.5%) diarrhoea 4.1% (placebo 1.4%) NCT03435081 · Phase 3 · registry result, not featured evidence 2 mg prostate cancer 9.1% (placebo 0%) upper respiratory tract infection 8.6% (placebo 6.2%) urinary tract infection 8.6% (placebo 2.1%) NCT03435081 · Phase 3 · registry result, not featured evidence 1 mg upper respiratory tract infection 6.1% (placebo 6.2%) back pain 2% (placebo 0.7%) blood creatine phosphokinase increased 2% (placebo 0.7%) NCT03435081 · Phase 3 · registry result, not featured evidence 1 mg upper respiratory tract infection 10.5% (placebo 6.2%) ovarian cyst ruptured 6.7% (placebo 0%) actinic keratosis 5.3% (placebo 0%) NCT03435081 · Phase 3 · registry result, not featured evidence 4 mg nasopharyngitis 15.3% (placebo 12%) folliculitis 5.4% (placebo 0%) upper respiratory tract infection 2.7% (placebo 1.9%) NCT03733301 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 11% (placebo 12%) upper respiratory tract infection 7.3% (placebo 1.9%) folliculitis 3.7% (placebo 0%) NCT03733301 · Phase 3 · registry result, not featured evidence 4 mg blood creatine phosphokinase increased 13.2% (placebo 2%) headache 13.2% (placebo 0%) nasopharyngitis 10.5% (placebo 4.1%) NCT02576938 · Phase 2 · registry result, not featured evidence 2 mg dermatitis atopic 8.1% (placebo 10.2%) gastrooesophageal reflux disease 5.4% (placebo 0%) headache 5.4% (placebo 0%) NCT02576938 · Phase 2 · registry result, not featured evidence | 0.75% Cream BIDh upper respiratory tract infection 9% (placebo 3.2%) nasopharyngitis 6% (placebo 1.6%) headache 3.7% (placebo 4%) NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 13 more results1.5% Cream BID upper respiratory tract infection 12% (placebo 3.2%) nasopharyngitis 10.3% (placebo 1.6%) headache 5.3% (placebo 4%) NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.75% cream BID nasopharyngitis 9.3% (placebo 0%) upper respiratory tract infection 7.6% (placebo 0.8%) application site pain 0.7% (placebo 6.5%) NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.5% cream BID nasopharyngitis 9.1% (placebo 0%) upper respiratory tract infection 7.7% (placebo 0.8%) application site pain 0.7% (placebo 6.5%) NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.5% Cream BID upper respiratory tract infection 10.7% nasopharyngitis 8.7% NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.75% Cream BID upper respiratory tract infection 13.8% (placebo 3.1%) covid-19 8.2% (placebo 1.5%) pyrexia 6.3% (placebo 0%) NCT04921969 · Phase 3 1.5% Cream BID upper respiratory tract infection 14.9% (placebo 3.1%) nasopharyngitis 13% (placebo 1.5%) covid-19 7.1% (placebo 1.5%) NCT04921969 · Phase 3 1.5% upper respiratory tract infection 10.3% (placebo 4.9%) nasopharyngitis 5.9% (placebo 4.9%) application site pain 1% (placebo 6.2%) NCT06238817 · Phase 3 · registry result, not featured evidence 1.5% BID application site reaction 1.4% (placebo 8.7%) NCT05127421 · Phase 2 · registry result, not featured evidence 1.5% Cream BID covid-19 6.1% back pain 4.1% headache 4.1% NCT04839380 · Phase 2 · registry result, not featured evidence 0.15% QD nasopharyngitis 5.9% (placebo 7.7%) upper respiratory tract infection 3.9% (placebo 5.8%) dermatitis atopic 2% (placebo 7.7%) NCT03011892 · Phase 2 · registry result, not featured evidence 0.5% QD nasopharyngitis 2% (placebo 7.7%) upper respiratory tract infection 2% (placebo 5.8%) dermatitis atopic 0% (placebo 7.7%) NCT03011892 · Phase 2 · registry result, not featured evidence 1.5% BID nasopharyngitis 5% (placebo 7.7%) upper respiratory tract infection 2.7% (placebo 5.8%) dermatitis atopic 1.5% (placebo 7.7%) NCT03011892 · Phase 2 · registry result, not featured evidence 1.5% QD nasopharyngitis 7.8% (placebo 7.7%) dermatitis atopic 3.9% (placebo 7.7%) upper respiratory tract infection 2% (placebo 5.8%) NCT03011892 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 16 weeks versus 8 weeks.
- ePopulation context differs: baseline_threshold differs (none recorded versus bsa>=3); prior_therapy differs (experienced versus none recorded).
- fAssessment timepoints differ: 24 weeks versus 8 weeks.
- gPopulation comparability has not been reviewed for 42 of these studies.
- hPopulation comparability has not been reviewed for 18 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
baricitinib
show 5 more results
show 15 more results
show 15 more results
show 15 more results
show 17 more results
show 15 more results
show 10 more results
show 15 more results
show 6 more results
show 10 more results
show 12 more results
show 12 more results
+ 25 further endpoints in the CSV export.
Ruxolitinib (Opzelura)
show 17 more results
show 5 more results
show 5 more results
show 11 more results
show 11 more results
show 11 more results
show 17 more results
show 17 more results
show 65 more results
show 17 more results
show 17 more results
show 17 more results
+ 42 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · Ruxolitinib (Opzelura)'s landscape